Neoplasia/BPH

	Multi-omics profiling identifies ESM1 as a key mediator of immunoevasion through the SPP1 pathway in bladder cancer. Sci Rep Zhang W, Deng LL, Xia YY, Wei MY, Liu ZS, Li Q, Chen GQ, Huang J, Tang YC, Gan TQ, Chen G, Tang KQ, He J. PMID: 41366275 [PubMed - indexed for MEDLINE]
	Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data. Prostate Cancer Prostatic Dis Shore N, Morgans AK, Paracha N, Gallagher E, Thom H, Aceituno D, Orishaba P, Stefani S, Trinh QD, Wallis CJD, Abrams KR, Boegemann M. PMID: 41366131 [PubMed - as supplied by publisher]
	[(68)Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [(68)Ga]Ga-PSMA-11. Eur J Nucl Med Mol Imaging Wang J, Li L, Chen J, Wang R, Xiang J, Peng X, Wang Y, Luo Y, Zhu L, Kung HF, Zhou Z, Xiao Y, Zhu Z. PMID: 41366119 [PubMed - as supplied by publisher]
	The role of non-FDG agents in PET imaging of bladder cancer. Semin Nucl Med Safarian A, Muin D, Unterrainer L, Hörmann A, Mattana F, Dragonetti V, Eiber M, Ceci F, Pirich C, Beheshti M. PMID: 41365768 [PubMed - as supplied by publisher]
	Time-dependent Treatment Effects of Prostate-specific Membrane Antigen Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer in the ENZA-p (ANZUP1901) Trial. Eur Urol Focus Chen W, Yoshida S, Kimura K, Arita Y, Fujii Y. PMID: 41365730 [PubMed - as supplied by publisher]
	Evaluation of kynurenine and tryptophan metabolism in bladder cancer: Diagnostic and prognostic implications of IDO1 polymorphism. Urol Oncol Kayar K, Kayar R, Sönmez D, Hakan MT, Horozo, Yüceba, Yayl, Verim L. PMID: 41365723 [PubMed - as supplied by publisher]
	Letter to the Editor Re: "Comparison of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities in the Detection of Biochemical Recurrence of Prostate Cancer and Assessment of the Role of Artificial Intelligence: A Systematic Review and Meta-analysis". Acad Radiol Martinez MJ. PMID: 41365722 [PubMed - as supplied by publisher]
	Re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144. Eur Urol Ho A, Sachdev S. PMID: 41365696 [PubMed - as supplied by publisher]
	The Prognosis of Urothelial Carcinoma Between Kidney Transplantation Recipients and Normal Patients: A Propensity Score-Matched Study. Cancer Med Taihao W, Chunkai D, Jingcheng L, Yichen Z. PMID: 41365531 [PubMed - indexed for MEDLINE]
	Validation of the PSMA PRIMARY Scoring System and Comparison to an E-PSMA Likert System for [68Ga]Ga-PSMA-11 PET/CT Interpretation in Men With Suspected Radiorecurrent Prostate Cancer. Clin Nucl Med Light A, Lazic S, Connor MJ, Tam H, Ahmed HU, Shah TT, Barwick TD. PMID: 41365507 [PubMed - indexed for MEDLINE]
	Image-guided intensity-modulated radiotherapy with reduced margins in patients with prostate cancer: Results of the RCMIGI randomized phase II trial. Radiother Oncol Riou O, Fenoglietto P, Jarlier M, Prunaretty J, Aillères N, Poinas G, Debuire P, MSc SG, Meignant L, Segui B, Moscardo CL, Charissoux M, Azria D. PMID: 41365376 [PubMed - as supplied by publisher]
	Expression of CXCL13 in clear cell renal cell carcinoma: Assisting clinical diagnosis and exploring the malignant biological mechanism. Biochem Biophys Res Commun Xiong F, Wang H, Dong G, Luan Y, Gao L, Zhao W, Song Y, Wen C, Wang Y, Gong J, Li Y, Zhang W, Wang Y. PMID: 41365162 [PubMed - as supplied by publisher]
	Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial. J Urol Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. PMID: 41364813 [PubMed - as supplied by publisher]
	Artificial Intelligence-Enabled Imaging for Predicting Preoperative Extraprostatic Extension in Prostate Cancer: Systematic Review and Meta-Analysis. J Med Internet Res Zhang X, Qi Y, Wang X, Chen H, Li J. PMID: 41364797 [PubMed - indexed for MEDLINE]
	RenSeg: Leveraging Unsupervised Segmentation Using Localization and Contour-Guided Quickshift for Renal Calculi and Carcinoma Segmentation and Classification. IEEE J Biomed Health Inform Faruk F, Alam HMS, Rahman R, Alam MGR, Jeong J, Hossain MK, Uddin J. PMID: 41364571 [PubMed - as supplied by publisher]
	Factors influencing trifecta outcomes following robot-assisted partial nephrectomy for stage I renal cell carcinoma using the Hugoâ„¢ RAS system: a prospective observational study and comparison with contemporary literature. J Robot Surg Solairaj D, Tyagi V, Tyagi A, Agarwal B. PMID: 41364415 [PubMed - indexed for MEDLINE]
	Patient perspectives on follow-up CT scans after treatment for renal cell carcinoma (RCC): a cross-sectional questionnaire study. Abdom Radiol (NY) Reijerink MAA, Stoker J, Zondervan PJ, Bipat S. PMID: 41364220 [PubMed - as supplied by publisher]
	Contrast enhanced ultrasound evaluation of nephron sparing treatment for renal cell carcinoma. Abdom Radiol (NY) Barr RG, Roccarina D, Mazzareilli L, Bauman P, Cheng K. PMID: 41364219 [PubMed - as supplied by publisher]
	Integrated multi-omics analysis identifies DARS2, MRTO4, and MRPL37 as novel biomarkers and potential therapeutic targets for bladder cancer. Discov Oncol Xiao L, Wang Y, Xiong Y, Zhuang Z, Hu C, Xiao Z. PMID: 41364147 [PubMed - as supplied by publisher]
	Global, regional, and national burdens of bladder cancer in individuals aged 60Â years and older from 1990 to 2021: a cross-sectional study. Int Urol Nephrol Zhang W, Wei Q, Han X, Zheng X, Zhang P. PMID: 41364142 [PubMed - as supplied by publisher]

Articles 1 - 20 / 183757

Page 1 of 9188



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy